Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Albany Molecular Research Inc (NASDAQ:AMRI)

Delayed Data
As of Nov 24
 +0.01 / +0.05%
Today’s Change
Today|||52-Week Range
Health Services
Services to the Health Industry

Company Description

Albany Molecular Research, Inc. engages in research and manufacturing organization providing customers drug discovery, development, and manufacturing services. The company operates through three segments: Discovery and Development Services, Active Pharmaceutical Ingredients and Drug Product. The Discovery and Development Services segment provides comprehensive services from hit identification to investigational new drug, including drug lead discovery, library design and synthesis, synthetic and medicinal chemistry, in vitro biology and pharmacology, lead optimization, chemical development, drug metabolism and pharmacokinetics and small-scale commercial manufacturing. The Active Pharmaceutical Ingredients segment includes pilot to commercial scale manufacturing of API, including intermediates and high potency and controlled substance manufacturing. The Drug Product segment includes formulation through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. The company was founded by Thomas E. D'Ambra on June 20, 1991 and is headquartered in Albany, NY.

Contact Information

Albany Molecular Research, Inc.
26 Corporate Circle
Albany New York 12203
P:(518) 512-2000
Investor Relations:
(518) 512-2261



Other institutional61.60%
Mutual fund holders30.65%
Individual stakeholders24.24%

Top Executives

William S. MarthPresident, Chief Executive Officer & Director
George SvokosChief Operating Officer
Felicia LadinChief Financial Officer, Treasurer & Senior VP
Jimmy WangChief Information Officer & Senior Vice President
Lori M. HendersonSecretary, Senior Vice President & General Counsel